Ir para o conteúdo principal

United States News Todas as matérias

Todas as matérias desta seção, das mais recentes às mais antigas — página 143 de 371.

Grafa

Merck gains EU approval for Keytruda plus Padcev in bladder cancer

Merck (NYSE:MRK) announced that the European Commission approved KEYTRUDA (pembrolizumab), in combination with Padcev (enfortumab vedotin-ejfv), as neoadjuvant treatment followed by adjuvant treatment after radical cystectomy for adults with resectable muscle-invasive bladder cancer who are ineligible for cisplatin-containing chemotherapy.

Leia mais: Merck gains EU approval for Keytruda plus Padcev in bladder cancer